Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 88 (2) , 378-385
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)American Heart Journal, 2010
- Antihypertensive Treatment With ACE Inhibitors or -Blockers and Risk of Incident Atrial Fibrillation in a General Hypertensive PopulationAmerican Journal of Hypertension, 2009
- Metabolic Syndrome and Risk of Development of Atrial FibrillationCirculation, 2008
- Predictors of new-onset decline in kidney function in a general middle-european populationNephrology Dialysis Transplantation, 2007
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAmerican Heart Journal, 2006
- Frequency of atrial fibrillation and factors related to its development in dialysis patientsInternational Journal of Cardiology, 2006
- Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)American Heart Journal, 2005
- Effects of Renin-Angiotensin Blockade on Sympathetic Reactivity and β-Adrenergic Pathway in the Spontaneously Hypertensive RatHypertension, 1997
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983
- Epidemiologic Features of Chronic Atrial FibrillationNew England Journal of Medicine, 1982